Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
163 hedge funds and large institutions have $1.17B invested in Acorda Therapeutics in 2013 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 64 increasing their positions, 47 reducing their positions, and 17 closing their positions.
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
36% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 47
24% more call options, than puts
Call options by funds: $1.22M | Put options by funds: $984K
7% more funds holding
Funds holding: 153 → 163 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less capital invested
Capital invested by funds: $1.4B → $1.17B (-$231M)
Top Buyers
| 1 |
Franklin Resources
San Mateo,
California
|
+$22M |
| 2 |
Goldman Sachs
New York
|
+$16.7M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$11.9M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$8.2M |
| 5 |
Renaissance Technologies
New York
|
+$8.14M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$66.1M |
| 2 |
FAM
Fred Alger Management
New York
|
-$23.4M |
| 3 |
JP Morgan Chase
New York
|
-$15.5M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$13.1M |
| 5 |
AG
Artal Group
Luxembourg
|
-$12.8M |
ACOR Hedge Fund Activity: Q4 2013 in Review
163 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2013, worth a combined $1.17B — down 17% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACOR positions and 17 closed out — a net gain of 11 holders — while 64 added to existing stakes and 47 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $22M. The largest seller was Fidelity Investments, cutting an estimated $66.1M.
- 163 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2013, up from 153 in Q3 2013.
- Funds reported $1.17B of Acorda Therapeutics stock for Q4 2013, down 17% quarter-over-quarter.
- 28 funds opened new Acorda Therapeutics positions in Q4 2013 and 17 closed out, a net change of +11 holders.
- The largest Acorda Therapeutics buyer in Q4 2013 was Franklin Resources, an estimated $22M added.
- The largest Acorda Therapeutics seller in Q4 2013 was Fidelity Investments, an estimated $66.1M sold.
Based on aggregated 13F filings for Q4 2013.